PATENT CLAIM ANALYSIS

Application Number: 16210330
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-03
Patent Classification: ["424", "277100"]

Abstract:
A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

Claim (Index 11):
The method of  claim 1 , wherein the cancer is lung cancer.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 98.0
- Lexical Diversity: 2.48148
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16153294', '16100498', '15637906', '15638072', '15849878']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7990585773054556
- 35 USC 102 Novelty (BERT): 0.5374515168784733
- Combined Prediction Score: 0.7728978712627573
- Mean Citation Score: 376.247742
- Max Citation Score: 381.77304
- Similarity Product: 227.71534534649845

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test